Written and peer-reviewed by physicians—but use at your own risk. Read our disclaimer.

banner image

amboss

Trusted medical answers—in seconds.

Get access to 1,000+ medical articles with instant search
and clinical tools.

Try free for 5 days

Lung cancer

Last updated: January 11, 2021

Summary

Lung cancer is the leading cause of cancer death worldwide, with approx. 90% of cases being attributable to smoking. Lung cancer is often divided into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC is characterized by its central location, rapid tumor growth, early metastases, and association with numerous paraneoplastic syndromes. NSCLC accounts for approx. 85% of all diagnoses of lung cancer. Histologic subtypes of NSCLC include peripheral adenocarcinoma and central squamous cell carcinoma. Patients with lung cancer are usually asymptomatic during the early stages of the disease. Late-stage disease may manifest with pulmonary (e.g., dyspnea, cough, hemoptysis, chest pain) or extrapulmonary symptoms (e.g., weight loss, finger clubbing), paraneoplastic syndromes (e.g., SIADH in SCLC), or signs of metastatic disease. Lung cancer most commonly spreads to the brain, liver, adrenal glands, and/or bones. Solitary pulmonary nodules detected on chest x-ray should raise suspicion for lung cancer and should be further evaluated using a chest CT scan. Bronchoscopy or CT-guided biopsy confirms the diagnosis. Patients with no evidence of distant metastases can undergo surgical resection of one or more pulmonary lobes with or without chemotherapy. As most of the patients are inoperable at the time of diagnosis, chemoradiotherapy remains a common modality of lung cancer treatment. Prognosis is generally poor, with a 5-year survival rate below 20% even with a multimodal approach.

Epidemiology

Epidemiological data refers to the US, unless otherwise specified.

Etiology

Smokers exposed to asbestos have a significantly higher risk of developing lung cancer compared to smokers that are not.

Classification

WHO classification of lung cancers [6][11]

Tumor type Location Characteristics Histology

Non-small cell lung cancer (NSCLC) [12]

Lung adenocarcinoma
  • Peripheral
Lung squamous cell carcinoma (SCC)
  • Central
Large cell carcinoma
  • Peripheral
  • Undifferentiated
  • Large tumor cells
Lung neuroendocrine tumors
Small cell lung cancer (SCLC)
  • Central

Large cell neuroendocrine carcinoma

  • Peripheral
  • Generally, high-grade tumors
  • Poor clinical prognosis
Bronchial carcinoid tumor
  • Central/peripheral

Step 2CK:” Smoking, Central, Chromogranin A, and Kulchitsky cells are the most important characteristics of small cell lung cancer.

Step 3CK:” Smoking, Central, Cavitary, hyperCalcemia, and Keratin pearls are the most important characteristics of squamous cell lung cancer.

Variants of lung cancer

Pancoast tumor [20][21]

Lymphangitic carcinomatosis

  • Spread of cancer cells along lymphatic vessels
  • On imaging, a streaky-reticular pattern may be observed.

Clinical features

Symptoms of lung cancer may be related to the local effects of the tumor in the lung or spread of disease beyond the chest. Lung cancer often only becomes symptomatic in late stages, generally affecting prognosis negatively.

Pulmonary symptoms [22]

Extrapulmonary symptoms [22]

Recurrent respiratory infections (e.g., pneumonia) in the same pulmonary region in patients ≥ 40 years old should always raise suspicion for lung cancer.

Symptoms of metastatic disease

Lung cancer loves to BLAB:” the most common sites of metastasis from lung cancer are the Brain, Liver, Adrenals, and Bones.

Paraneoplastic syndromes of lung cancer [23]

Pathology

Non-small cell lung cancer [11]

Squamous cell carcinoma

Adenocarcinoma [14]

  • Characteristics
    • Glandular tumor
    • Mucin-producing cells (positive mucin staining)
  • Immunohistochemical makers: expression of napsin A and TTF-1
  • Historical terminology
    • Bronchioloalveolar carcinoma (BAC): obsolete term for well-differentiated, noninvasive adenocarcinomas that grow along the alveolar septa.
      • Today, adenocarcinomas of the lung are rather described on a spectrum of lepidic growth.
      • Lepidic growth: noninvasive tumor growth at intact alveoli.
      • BAC has been replaced by a variety of adenocarcinoma subtypes (see “Preinvasive subtypes” and “Invasive subtypes” below)
  • Preinvasive subtypes
    • Atypical adenomatous hyperplasia (AAH)
      • Atypical pneumocyte growth along alveolar walls without cytological features of carcinoma
      • Size: ≤ 5 mm
    • Pulmonary adenocarcinoma in situ (formerly BAC)
      • Small (≤ 3 cm) nodule with a lepidic growth pattern
      • Lacks any component of invasion
  • Invasive subtypes (classified according to the predominant histopathological growth pattern)
    • Minimally-invasive pulmonary adenocarcinoma (MIA)
      • Small (≤ 3 cm) tumor with a predominantly lepidic pattern
      • ≤ 5 mm of invasion
    • Lepidic-predominant adenocarcinoma (formerly nonmucinous BAC)
      • Tumor primarily shows intraalveolar growth
      • At least one focus of invasion > 5 mm
    • Mucinous-predominant adenocarcinoma (formerly mucinous BAC)
      • Goblet cell or columnar cell growth along alveolar septae
      • Multiple areas of invasion
  • Additional subtypes

Large cell carcinoma

  • Poorly differentiated, large polygonal tumor cells (abundant cytoplasm)
  • Prominent nucleoli
  • Lacks identifiable glandular, squamous, or neuroendocrine elements on microscopy or immunohistochemistry.
    • Definitive diagnosis cannot be made by biopsy, rather it can only be finalized from completely excised surgical specimens.

Neuroendocrine tumors [31]

Small cell lung cancer

Large cell neuroendocrine carcinoma

Bronchial carcinoid

Diagnostics

Workup of an incidental solitary pulmonary nodule [34]

  • Solitary pulmonary nodule: a small (≤ 30 mm), well-defined lesion in the pulmonary parenchyma with no lymph node enlargement
  • Diagnostic approach
    • Applies to individuals who are otherwise healthy, asymptomatic, > 35 years of age
    • Evaluation of high-risk groups via lung cancer screening is discussed in the “Prevention” section below.
  • Diagnostic steps
    • Obtain dedicated chest CT if nodule discovered on chest x-ray or other imaging modality.
    • Compare to previous x-rays or CT scans if available.
    • Perform malignancy risk assessment (based on CT findings and patient characteristics).
    • The decision to pursue serial imaging, PET/CT, biopsy, or surgical excision should be based on individualized patient factors:

Malignancy risk assessment for solitary pulmonary nodules [35][36][37][38]

Risk factor Low risk (< 5%) Intermediate risk (5–65%) High risk (> 65%)
Nodule size (mm) < 8 8–20 > 20

Patient age (years)

< 40 40–60 > 60
Smoking status Never Current or past Current or past

Nodule location

Lower/middle lobe Upper lobe Upper lobe
Nodule border Smooth Scalloped Spiculated

In patients aged > 40 years, any pulmonary nodule detected on chest x-ray should be considered lung cancer until proven otherwise.

Imaging [39]

Chest x-ray

CT chest

  • Every patient with suspected lung cancer should receive a dedicated chest CT (IV contrast preferable).
  • Allows for the delineation of the primary tumor and the assessment of mediastinal lymph node involvement
  • Relatively insensitive for detection of lymph node metastases [35]
  • Radiographic findings associated with increased risk of malignancy [37][42]
    • Irregular margins (i.e., scalloped or spiculated)
    • Large size (> 2 cm)
    • Upper lobe location
    • Absent calcifications
    • Air bronchograms
    • Subsolid nodule (e.g., ground-glass or part-solid) [43]

PET/CT [44]

Imaging for suspected metastatic disease

  • Site-specific imaging should be symptom- or CT-directed
  • Tissue confirmation of metastatic disease is strongly recommended for all patients.

Tissue biopsy [47]

Tissue biopsy is the confirmatory test required for the diagnosis of lung cancer.

Laboratory studies

Stages

Staging of NSCLC [49][50]

The staging of NSCLC is based on the AJCC TNM staging system. This classification defines four stages, corresponding to cancer spread.

Management approach AJCC TNM Description

Curative

  • Stage IA
  • T1, N0, M0
  • Stage IB
  • T2a, N0, M0
  • Stage IIA
  • T2b, N0, M0
  • Stage IIB
  • T1-2, N1, M0
  • T3, N0, M0

Intermediate (curative)

  • Stage IIIA
  • T1-2, N2, M0
  • T3-4, N1, M0
  • T4, N0, M0
  • Stage IIIB
  • T1-2, N3, M0
  • T3-4, N2, M0
  • Stage IIIC
  • T3-4, N3, M0
Palliative
  • Stage IVA
  • T1-4, N0-3, M1a-b
  • Stage IVB
  • T1-4, N0-3, M1c
  • Any tumor size
  • Any nodal involvement
  • Multiple extrathoracic metastases (M1c)

As soon as distant metastases are detected, the cancer is classified as AJCC stage IV.

Staging of SCLC [31]

Staging of SLCS is based on the extent of tumor spread within or beyond one hemithorax and includes two major stages: limited stage (LS-SCLC) and extensive stage (ES-SCLS). The TNM staging system can be used as well.

Stage Classification Corresponding TNM Cancer spread Cancer stage at diagnosis
Curative
  • Limited stage
  • T1-2, N0-1
  • Approx. 30%
  • T3-4, N0-1
  • T1-4, N2-3
Palliative
  • Extensive stage
  • M1a-c
  • Approx. 70%

Differential diagnoses

Differential diagnosis of pulmonary nodules [51]

Differential diagnosis

Examples Features
Primary lung cancer
  • Single central or peripheral nodule
  • Irregular margins and/or spicules
  • No calcifications or irregular calcifications
  • Size is typically > 2 cm
Lung metastases [52]
  • More commonly multiple pulmonary nodules
Pulmonary neuroendocrine tumor
  • If centrally located, endobronchial nodule or perihilar mass [53]
  • If peripherally located, round or oval opacities
  • Size typically 2–5 cm
Benign tumors [54][55]
Infectious granulomas
  • Round, well-defined, calcified nodule
  • Most common cause of benign pulmonary nodules (∼ 80%) [57]
Inflammatory conditions
  • Multiple bilateral cavitating nodular lesions [58]
  • Commonly associated with other systemic findings

Pulmonary nodules are more commonly metastases of other cancers than primary lung cancer.

The differential diagnoses listed here are not exhaustive.

Treatment

Surgical resection with or without chemotherapy is the standard of care for early-stage (e.g., stage I and stage IIA) lung cancers. Radiotherapy is the treatment of choice for patients with inoperable early-stage disease (either due to poor pulmonary reserve or medical comorbidities). Treatment of locally-advanced NSCLC and LS-SCLC (e.g., stage IIB–IIIC) requires a multimodal approach with chemotherapy, radiotherapy, surgical resection, and immunotherapy. Most cases of lung cancer are diagnosed at an advanced (i.e., metastatic) stage and are therefore treated palliatively with chemotherapy and immunotherapy. As it is used in nearly every stage of treatment, chemotherapy is the mainstay of lung cancer therapy.

Overview [31][49][59][60][61]

Cancer type Tumor stage Treatment approach Regimen
NSCLC

Stage I–IIA

  • Curative
  • Preferred treatment: surgical resection with or without adjuvant chemotherapy [62][63]
  • Surgically inoperable: stereotactic ablative radiotherapy (SABR)
Stage IIB–IIIC
  • If surgically resectable (see “Relative contraindications to surgery” in “Surgical management” below) [64]
  • If unresectable: concurrent chemoradiation followed by adjuvant immunotherapy

Stage IVA–B

  • Palliative
SCLC Limited stage
  • Curative
Extensive stage
  • Palliative
  • Standard treatment: chemotherapy or chemoimmunotherapy
  • PCI: only in patients with good response to initial systemic therapy

Although SCLC generally has a good initial response to chemotherapy, the rate of recurrence is high.

Therapeutic options

Medical therapy

Radiation therapy (including prophylactic cranial irradiation)

Surgical management

  • Indications: preferred local treatment modality for early-stage tumors and stage III tumors without nodal involvement [49]
  • Relative contraindications to surgery
    • N3 disease
    • Bulky N2 disease (> 3 cm)
    • Multiple N2 nodes
  • Complications [78]

Approx. 65% of patients with lung cancer are inoperable at the time of diagnosis.

Surgical procedures [49]

Pulmonary resection may be performed either as an open procedure or as video-assisted thoracoscopic surgery. See also “Preoperative pulmonary assessment” for workup in patients undergoing surgery.

Advantages and disadvantages of surgical procedures

Type of resection

Definition Advantages Disadvantages
Lobectomy
  • Anatomic resection of a pulmonary lobe
  • Complete resection of the tumor with a wider safety margin
  • Can only be performed if the patient's FEV1 > 1.5 L and DLCO > 60% [79][80]
Sublobar resection
  • Only appropriate for small (i.e., 2–3 cm) tumors in the peripheral lung with at least one of the following:
    • Pure AIS histology
    • Nodule ≥ 50% ground-glass appearance on CT
    • Radiologic evidence of slow doubling-time (≥ 400 days)
Pneumonectomy
  • Complete lung resection
  • Useful for cancers that involve the hilum or main bronchi or that extend across a major fissure
  • High perioperative mortality
  • High incidence of pulmonary and cardiovascular complications
  • A lung-sparing anatomic resection (e.g., sleeve lobectomy) is preferred over pneumonectomy if margin-negative resection can be achieved. [81][82]

Prognosis

  • Overall 5‑year survival rate: approx. 20% [1]
  • SCLC [83]
    • Limited disease 5-year survival: 16% (median survival up to 20 months)
    • Extended disease 5-year survival: 3% (median survival up to 13 months)
  • NSCLC
    • Better prognosis
    • Depends primarily on the extent of disease and lymph node status
    • Locally confined stages (no lymph node involvement, no metastasis) have a 5-year survival rate of approx. 60–70%. [84]

Prevention

Cessation of smoking

  • Complete cessation is associated with a 40–50% reduction in risk for developing lung cancer after 5–10 years. [85][86]
  • Longer periods of abstinence lead to greater reductions in lung cancer risk. [87]
  • After approx. 15–20 years, the risk decreases to the corresponding level in nonsmokers. [88]

Lung cancer screening

  • Annual screening with low-dose CT imaging
    • Associated with a decrease in lung cancer-specific mortality [89][90]
    • Multiple oncology and thoracic societies have varying recommendations regarding the specifics of which patients should be screened. [91]
    • The U.S. Preventive Services Task Force (USPSTF) recommendation: patients aged 55–80 years with a history of smoking (≥ 30 pack-years) and who currently smoke or stopped within the past 15 years [92]

References

  1. Cancer Stat Facts: Lung and Bronchus Cancer. https://seer.cancer.gov/statfacts/html/lungb.html. . Accessed: August 10, 2020.
  2. Leading Cancer Cases and Deaths, All Races/Ethnicities, Male and Female, 2017. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Updated: June 1, 2020. Accessed: August 10, 2020.
  3. Siddiqui F, Siddiqui AH. Lung Cancer. StatPearls. 2020 .
  4. Jemal A, Travis WD, Tarone RE, Travis L, Devesa SS. Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type.. International journal of cancer. 2003; 105 (1): p.101-7. doi: 10.1002/ijc.11020 . | Open in Read by QxMD
  5. Hecht SS. Tobacco smoke carcinogens and lung cancer.. J Natl Cancer Inst. 1999; 91 (14): p.1194-210. doi: 10.1093/jnci/91.14.1194 . | Open in Read by QxMD
  6. Dela cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32 (4): p.605-644. doi: 10.1016/j.ccm.2011.09.001 . | Open in Read by QxMD
  7. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of Lung Cancer. Chest. 2013; 143 (5): p.e1S-e29S. doi: 10.1378/chest.12-2345 . | Open in Read by QxMD
  8. Kreuzer M, Müller KM, Brachner A, et al. Histopathologic findings of lung carcinoma in German uranium miners. Cancer. 2000; 89 (12): p.2613-2621. doi: 10.1002/1097-0142(20001215)89:12<2613::aid-cncr14>3.0.co;2-y . | Open in Read by QxMD
  9. Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, Asbestosis, Smoking, and Lung Cancer. New Findings from the North American Insulator Cohort. Am J Respir Crit Care Med. 2013; 188 (1): p.90-96. doi: 10.1164/rccm.201302-0257oc . | Open in Read by QxMD
  10. Bobba RK, Holly JS, Loy T, Perry MC. Scar Carcinoma of the Lung: A Historical Perspective. Clin Lung Cancer. 2011; 12 (3): p.148-154. doi: 10.1016/j.cllc.2011.03.011 . | Open in Read by QxMD
  11. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors. J Thorac Oncol. 2015; 10 (9): p.1243-1260. doi: 10.1097/jto.0000000000000630 . | Open in Read by QxMD
  12. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.. Mayo Clinic proceedings. 2008; 83 (5): p.584-94. doi: 10.4065/83.5.584 . | Open in Read by QxMD
  13. Hu Y, Ulrich BC, Supplee J, et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.. Clin Cancer Res. 2018; 24 (18): p.4437-4443. doi: 10.1158/1078-0432.CCR-18-0143 . | Open in Read by QxMD
  14. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011; 6 (2): p.244-285. doi: 10.1097/jto.0b013e318206a221 . | Open in Read by QxMD
  15. Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men.. Chest. 1997; 112 (6): p.1474-9. doi: 10.1378/chest.112.6.1474 . | Open in Read by QxMD
  16. Harris K, Khachaturova I, Azab B, et al. Small Cell Lung Cancer Doubling Time and its Effect on Clinical Presentation: A Concise Review. Clin Med Insights Oncol. 2012; 6 : p.CMO.S9633. doi: 10.4137/cmo.s9633 . | Open in Read by QxMD
  17. Nau MM, Brooks BJ, Battey J, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985; 318 (6041): p.69-73. doi: 10.1038/318069a0 . | Open in Read by QxMD
  18. Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer. 2008; 113 (1): p.5-21. doi: 10.1002/cncr.23542 . | Open in Read by QxMD
  19. Survival Rates for Lung Carcinoid Tumors. https://www.cancer.org/cancer/lung-carcinoid-tumor/detection-diagnosis-staging/survival-rates.html. Updated: January 8, 2020. Accessed: August 10, 2020.
  20. Bruzzi JF, Komaki R, Walsh GL, et al. Imaging of Non–Small Cell Lung Cancer of the Superior Sulcus. Radiographics. 2008; 28 (2): p.551-560. doi: 10.1148/rg.282075709 . | Open in Read by QxMD
  21. Selim M. Arcasoy, James R. Jett. Superior Pulmonary Sulcus Tumors and Pancoast's Syndrome. N Engl J Med. 1997; 337 (19): p.1370-1376. doi: 10.1056/nejm199711063371907 . | Open in Read by QxMD
  22. Spiro SG, Gould MK, Colice GL. Initial Evaluation of the Patient With Lung Cancer: Symptoms, Signs, Laboratory Tests, and Paraneoplastic Syndromes. Chest. 2007; 132 (3): p.149S-160S. doi: 10.1378/chest.07-1358 . | Open in Read by QxMD
  23. Hauber H-P. Paraneoplastische Syndrome beim Lungenkarzinom. Pneumologie. 2011; 65 (06): p.347-358. doi: 10.1055/s-0030-1256118 . | Open in Read by QxMD
  24. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2012; 119 (3): p.648-655. doi: 10.1002/cncr.27772 . | Open in Read by QxMD
  25. Clinical Practice Guidelines in Oncology: Cancer-Associated Venous Thromboembolic Disease, Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Updated: April 16, 2020. Accessed: August 10, 2020.
  26. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357 (9250): p.96-100. doi: 10.1016/s0140-6736(00)03540-6 . | Open in Read by QxMD
  27. Fusco FD, Rosen SW. Gonadotropin-Producing Anaplastic Large-Cell Carcinomas of the Lung. N Engl J Med. 1966; 275 (10): p.507-515. doi: 10.1056/nejm196609082751001 . | Open in Read by QxMD
  28. Vicier C, Tabouret E, Tallet A, et al. BetaHCG secretion by a pulmonary adenocarcinoma. World J Surg Oncol. 2013; 11 (1): p.228. doi: 10.1186/1477-7819-11-228 . | Open in Read by QxMD
  29. Yap FY, Skalski MR, Patel DB, et al. Hypertrophic Osteoarthropathy: Clinical and Imaging Features. Radiographics. 2017; 37 (1): p.157-195. doi: 10.1148/rg.2017160052 . | Open in Read by QxMD
  30. NCCN clinical Practice Guidelines in Oncology: Non-small cell lung cancer, Version 6.2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Updated: June 15, 2020. Accessed: August 10, 2020.
  31. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11 (1): p.39-51. doi: 10.1016/j.jtho.2015.09.009 . | Open in Read by QxMD
  32. NCCN - Clinical Practice Guidelines in Oncology: Small cell lung cancer, Version 1.2021. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Updated: August 4, 2020. Accessed: August 10, 2020.
  33. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017; 284 (1): p.228-243. doi: 10.1148/radiol.2017161659 . | Open in Read by QxMD
  34. Gould MK, Donington J, Lynch WR, et al. Evaluation of Individuals With Pulmonary Nodules: When Is It Lung Cancer?. Chest. 2013; 143 (5): p.e93S-e120S. doi: 10.1378/chest.12-2351 . | Open in Read by QxMD
  35. Gould MK, Ananth L, Barnett PG. A Clinical Model To Estimate the Pretest Probability of Lung Cancer in Patients With Solitary Pulmonary Nodules. Chest. 2007; 131 (2): p.383-388. doi: 10.1378/chest.06-1261 . | Open in Read by QxMD
  36. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.. Arch Intern Med. 1997; 157 (8): p.849-55.
  37. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of Cancer in Pulmonary Nodules Detected on First Screening CT. N Engl J Med. 2013; 369 (10): p.910-919. doi: 10.1056/nejmoa1214726 . | Open in Read by QxMD
  38. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for Staging Non-small Cell Lung Cancer. Chest. 2013; 143 (5): p.e211S-e250S. doi: 10.1378/chest.12-2355 . | Open in Read by QxMD
  39. Kundel HL. Predictive value and threshold detectability of lung tumors.. Radiology. 1981; 139 (1): p.25-29. doi: 10.1148/radiology.139.1.7208937 . | Open in Read by QxMD
  40. Vikas Pathak, Iliana Samara Hurtado Rendon. Pulmonary adenocarcinoma masquerading as diffuse inflammatory interstitial lung disease. Respiratory Medicine CME. 2011; 4 (2): p.67-69. doi: 10.1016/j.rmedc.2010.09.003 . | Open in Read by QxMD
  41. Cummings SR, Lillington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules. A Bayesian approach.. Am Rev Respir Dis. 1986; 134 (3): p.449-52. doi: 10.1164/arrd.1986.134.3.449 . | Open in Read by QxMD
  42. Li F, Sone S, Abe H, MacMahon H, Doi K. Malignant versus Benign Nodules at CT Screening for Lung Cancer: Comparison of Thin-Section CT Findings. Radiology. 2004; 233 (3): p.793-798. doi: 10.1148/radiol.2333031018 . | Open in Read by QxMD
  43. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roqué i Figuls M. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014 . doi: 10.1002/14651858.cd009519.pub2 . | Open in Read by QxMD
  44. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to Diagnose Lung Cancer in Areas With Infectious Lung Disease. JAMA. 2014; 312 (12): p.1227. doi: 10.1001/jama.2014.11488 . | Open in Read by QxMD
  45. Subedi N, Scarsbrook A, Darby M, et al. The clinical impact of integrated FDG PET–CT on management decisions in patients with lung cancer. Lung Cancer. 2009; 64 (3): p.301-307. doi: 10.1016/j.lungcan.2008.09.006 . | Open in Read by QxMD
  46. Rivera MP, Mehta AC, Wahidi MM. Establishing the Diagnosis of Lung Cancer. Chest. 2013; 143 (5): p.e142S-e165S. doi: 10.1378/chest.12-2353 . | Open in Read by QxMD
  47. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8 (7): p.823-859. doi: 10.1097/jto.0b013e318290868f . | Open in Read by QxMD
  48. Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers. 2018; 10 (3): p.72. doi: 10.3390/cancers10030072 . | Open in Read by QxMD
  49. Chirieac LR. Tumor cell proliferation, proliferative index and mitotic count in lung cancer.. Translational lung cancer research. 2016; 5 (5): p.554-556. doi: 10.21037/tlcr.2016.10.10 . | Open in Read by QxMD
  50. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012; 25 (S1): p.S18-S30. doi: 10.1038/modpathol.2011.150 . | Open in Read by QxMD
  51. Choromańska A, Macura KJ. Evaluation of Solitary Pulmonary Nodule Detected During Computed Tomography Examination. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403798/#. 2012; 77 (2): p.22-34. doi: 10.12659/pjr.882967 . | Open in Read by QxMD
  52. Caparica R, Mak MP, Rocha CH, et al. Pulmonary Nodules in Patients With Nonpulmonary Cancer: Not Always Metastases. J Glob Oncol. 2016; 2 (3): p.138-144. doi: 10.1200/jgo.2015.002089 . | Open in Read by QxMD
  53. Jeung M-Y, Gasser B, Gangi A, et al. Bronchial Carcinoid Tumors of the Thorax: Spectrum of Radiologic Findings. Radiographics. 2002; 22 (2): p.351-365. doi: 10.1148/radiographics.22.2.g02mr01351 . | Open in Read by QxMD
  54. Chen C-H, Liao W-C, Tu C-Y. Lung mass with popcorn calcification. QJM. 2014; 108 (4): p.341-341. doi: 10.1093/qjmed/hcu191 . | Open in Read by QxMD
  55. Siegelman SS, Khouri NF, Scott WW, et al. Pulmonary hamartoma: CT findings.. Radiology. 1986; 160 (2): p.313-317. doi: 10.1148/radiology.160.2.3726106 . | Open in Read by QxMD
  56. Pulmonary hamartoma. https://radiopaedia.org/articles/pulmonary-hamartoma-1. Updated: January 1, 2020. Accessed: August 26, 2020.
  57. Ost D, Fein AM, Feinsilver SH. The Solitary Pulmonary Nodule. N Engl J Med. 2003; 348 (25): p.2535-2542. doi: 10.1056/nejmcp012290 . | Open in Read by QxMD
  58. Parkar AP, Kandiah P. Differential Diagnosis of Cavitary Lung Lesions. J Belg Soc Radiol. 2016; 100 (1). doi: 10.5334/jbr-btr.1202 . | Open in Read by QxMD
  59. Howington JA, Blum MG, Chang AC, et al. Treatment of Stage I and II Non-small Cell Lung Cancer. Chest. 2013; 143 (5): p.e278S-e313S. doi: 10.1378/chest.12-2359 . | Open in Read by QxMD
  60. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of Stage III Non-small Cell Lung Cancer. Chest. 2013; 143 (5): p.e314S-e340S. doi: 10.1378/chest.12-2360 . | Open in Read by QxMD
  61. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of Small Cell Lung Cancer. Chest. 2013; 143 (5): p.e400S-e419S. doi: 10.1378/chest.12-2363 . | Open in Read by QxMD
  62. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26 (31): p.5043-5051. doi: 10.1200/jco.2008.16.4855 . | Open in Read by QxMD
  63. Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26 (21): p.3552-3559. doi: 10.1200/jco.2007.13.9030 . | Open in Read by QxMD
  64. Treatment Choices for Non-Small Cell Lung Cancer, by Stage. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/by-stage.html. Updated: June 10, 2020. Accessed: August 10, 2020.
  65. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379 (24): p.2342-2350. doi: 10.1056/nejmoa1809697 . | Open in Read by QxMD
  66. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2016; 375 (19): p.1823-1833. doi: 10.1056/nejmoa1606774 . | Open in Read by QxMD
  67. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2018; 378 (22): p.2078-2092. doi: 10.1056/nejmoa1801005 . | Open in Read by QxMD
  68. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379 (23): p.2220-2229. doi: 10.1056/nejmoa1809064 . | Open in Read by QxMD
  69. Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer. JAMA Oncol. 2018; 4 (9): p.1263. doi: 10.1001/jamaoncol.2018.1251 . | Open in Read by QxMD
  70. Timmerman R, Paulus R, Galvin J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010; 303 (11): p.1070. doi: 10.1001/jama.2010.261 . | Open in Read by QxMD
  71. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst. 2011; 103 (19): p.1452-1460. doi: 10.1093/jnci/djr325 . | Open in Read by QxMD
  72. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17 (12): p.1672-1682. doi: 10.1016/s1470-2045(16)30532-0 . | Open in Read by QxMD
  73. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393 (10185): p.2051-2058. doi: 10.1016/s0140-6736(18)32487-5 . | Open in Read by QxMD
  74. Pignon J-P, Arriagada R, Ihde DC, et al. A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer. N Engl J Med. 1992; 327 (23): p.1618-1624. doi: 10.1056/nejm199212033272302 . | Open in Read by QxMD
  75. Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission. N Engl J Med. 1999; 341 (7): p.476-484. doi: 10.1056/nejm199908123410703 . | Open in Read by QxMD
  76. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18 (5): p.663-671. doi: 10.1016/s1470-2045(17)30230-9 . | Open in Read by QxMD
  77. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015; 385 (9962): p.36-42. doi: 10.1016/s0140-6736(14)61085-0 . | Open in Read by QxMD
  78. Ziarnik E, Grogan EL. Postlobectomy Early Complications. Thorac Surg Clin. 2015; 25 (3): p.355-364. doi: 10.1016/j.thorsurg.2015.04.003 . | Open in Read by QxMD
  79. Berry MF, Yang CJ, Hartwig MG, et al. Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer.. Ann Thorac Surg. 2015; 100 (1): p.271-6. doi: 10.1016/j.athoracsur.2015.02.076 . | Open in Read by QxMD
  80. Gould G, Pearce A. Assessment of suitability for lung resection. Continuing Education in Anaesthesia Critical Care & Pain. 2006; 6 (3): p.97-100. doi: 10.1093/bjaceaccp/mkl016 . | Open in Read by QxMD
  81. Deslauriers J, Grégoire J, Jacques LF, et al. Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences. Ann Thorac Surg. 2004; 77 (4): p.1152-1156. doi: 10.1016/j.athoracsur.2003.07.040 . | Open in Read by QxMD
  82. Li Z, Chen W, Xia M, et al. Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2019; 8 (6): p.775-786. doi: 10.21037/tlcr.2019.10.11 . | Open in Read by QxMD
  83. Lung Cancer Survival Rates. https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Updated: January 9, 2020. Accessed: December 17, 2020.
  84. Lung and Bronchus Cancer SEER 5-Year Relative Survival Rates, 2010-2016. https://seer.cancer.gov/explorer/application.html?site=47&data_type=4&graph_type=5&compareBy=subtype&chk_subtype_612=612&chk_subtype_613=613&chk_subtype_611=611&chk_subtype_610=610&series=age_range&chk_age_range_1=1&chk_age_range_9=9&chk_age_range_141=141&chk_age_range_157=157&sex=1&race=1&stage=101&advopt_precision=1&advopt_display=2#fnote_site. . Accessed: August 11, 2020.
  85. Godtfredsen NS, Prescott E, Osler M. Effect of Smoking Reduction on Lung Cancer Risk. JAMA. 2005; 294 (12): p.1505. doi: 10.1001/jama.294.12.1505 . | Open in Read by QxMD
  86. Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. J Natl Cancer Inst. 2018 . doi: 10.1093/jnci/djy041 . | Open in Read by QxMD
  87. Ebbert JO, Yang P, Vachon CM, et al. Lung Cancer Risk Reduction After Smoking Cessation: Observations From a Prospective Cohort of Women. J Clin Oncol. 2003; 21 (5): p.921-926. doi: 10.1200/jco.2003.05.085 . | Open in Read by QxMD
  88. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women.. JAMA. 2008; 299 (17): p.2037-47. doi: 10.1001/jama.299.17.2037 . | Open in Read by QxMD
  89. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med. 2011; 365 (5): p.395-409. doi: 10.1056/nejmoa1102873 . | Open in Read by QxMD
  90. De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382 (6): p.503-513. doi: 10.1056/nejmoa1911793 . | Open in Read by QxMD
  91. Lung Cancer Screening Guidelines and Recommendations. https://www.cdc.gov/cancer/lung/pdf/lung-cancer-screening-recommendations-508.pdf. Updated: September 21, 2019. Accessed: August 11, 2020.
  92. Moyer VA. Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014; 160 (5): p.330-338. doi: 10.7326/m13-2771 . | Open in Read by QxMD
  93. Kaldas MV. Dermatologic Manifestations of Pulmonary Disease. Dermatologic Manifestations of Pulmonary Disease. New York, NY: WebMD. http://emedicine.medscape.com/article/1094030-overview. Updated: January 21, 2015. Accessed: February 27, 2017.
  94. Nickloes TA. Superior Vena Cava Syndrome. Superior Vena Cava Syndrome. New York, NY: WebMD. http://emedicine.medscape.com/article/460865-overview. Updated: October 10, 2016. Accessed: February 27, 2017.
  95. Dhawan R. Hypertrophic Osteoarthropathy. Hypertrophic Osteoarthropathy. New York, NY: WebMD. http://emedicine.medscape.com/article/333735-overview. Updated: April 16, 2015. Accessed: February 27, 2017.